Neurogene sells 3.5 million shares at $30.00; net proceeds expected near $134.8 million
Neurogene agreed on June 30, 2026 to sell 3,500,000 common shares at $30.00 each, with pre-funded warrants for up to 666,666 more shares offered in place of common stock for some investors. Underwriters exercised in full their option to buy 624,999 additional shares on July 1, 2026, and the company expects net proceeds of about $134.8 million. The company says these proceeds, plus existing cash, will fund operations into the first quarter of 2029, but the sale adds new shares outstanding for existing shareholders.
Key points
- 3,500,000 common shares offered at $30.00 per share, plus pre-funded warrants for up to 666,666 shares
- Underwriters exercised in full their option for up to 624,999 additional shares on July 1, 2026
- Expected net proceeds of approximately $134.8 million after underwriting discounts and estimated expenses
- Offering expected to close July 2, 2026; company expects cash to last into the first quarter of 2029
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 01, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.